FDA Entry Point: Full-Stack U.S. Agent & FDA Compliance Firm

What FDA Entry Point is — and what it is not

FDA Entry Point is a private, independent U.S.-based regulatory compliance firm for foreign manufacturers and importers selling FDA-regulated products into the United States. It is not the U.S. Food and Drug Administration, not an FDA filing portal such as Cosmetics Direct or FURLS, and not the generic regulatory concept of an “entry point” or importer-of-record function. According to the company’s site, its role is to act as the client’s designated U.S. Agent and FDA point of contact, then handle related compliance work around registration, listing, submissions, and renewals across multiple product categories. FDA Entry Point

That distinction matters because buyers often conflate three different things: the legal requirement to appoint a U.S. Agent, the FDA’s own electronic systems, and the outside firm they hire to manage the work. FDA’s systems are where certain submissions are filed; a service firm is the outside party that prepares, submits, tracks, and manages those obligations on the manufacturer’s behalf. FDA Entry Point positions itself in that third category. FDA Cosmetics Direct user guide

Who usually looks for a firm like this

This kind of service is most relevant to foreign companies that need a legally valid U.S. point of contact and do not want to manage FDA registration mechanics, renewal calendars, and submission systems internally. That includes first-time exporters, lean operations teams without in-house regulatory staff, and larger manufacturers whose compliance leads already cover multiple markets.

The practical buying question is usually not “Do we need a U.S. Agent?” but “Do we only need a name on file, or do we need someone who can also keep the rest of the compliance work from slipping?” For companies entering the U.S. across food, cosmetics, devices, or drugs, that second question tends to determine whether a mailbox-style provider is enough.

What a U.S. Agent does in FDA terms

For foreign manufacturers, the U.S. Agent is the FDA’s domestic point of contact for certain communications, inspection coordination, and urgent notices. In the device context, FDA says foreign establishments must identify a U.S. Agent as part of establishment registration, and that the agent must maintain a real U.S. place of business and be available during normal business hours; a post office box or answering service alone does not satisfy the role. FDA U.S. Agents guidance

FDA Entry Point’s own explanation of the role tracks that pattern across food, drugs, devices, and cosmetics: serving as the FDA contact, helping facilitate inspections, relaying urgent notices, and keeping agent information current. That is the baseline legal function. The company’s positioning is that it layers broader compliance execution on top of that baseline rather than stopping at mail forwarding. FDA Entry Point FAQs

What FDA Entry Point appears to cover under one relationship

According to its public site, FDA Entry Point works across four major FDA-regulated verticals: Food & Beverage, Drugs & Pharma, Cosmetics, and Medical Devices. The company presents the U.S. Agent role as the anchor service, then adds adjacent compliance work that foreign manufacturers often need to stay market-ready. FDA Entry Point

• U.S. Agent designation and FDA point-of-contact coverage for foreign facilities
• Facility or establishment registration support
• Product listing support
• Label review work, including cosmetic INCI and claims review
• Drug SPL submission support and device GUDID/UDI support
• Prior Notice filing for food imports
• MoCRA Responsible Person support for cosmetics
• Renewal tracking and ongoing registration maintenance

How the service map lines up with FDA obligations

FDA Prior Notice guidance; FDA GUDID submission guidance; FDA human drug imports

Why some buyers choose a full-stack firm instead of a mailbox-only agent

A pattern worth naming: the U.S. Agent requirement is simple on paper, but the surrounding compliance work is where many teams actually struggle. The agent designation itself is only one field in a broader operating system of registrations, listings, submission formats, renewal windows, and import-facing deadlines.

For example, food importers need Prior Notice submitted and confirmed before arrival at the first U.S. port, with timing rules that vary by transport mode. Device labelers may need to maintain GUDID records, and bulk GUDID submission can run through HL7 SPL via the FDA Electronic Submissions Gateway. Drug manufacturers face establishment registration and listing obligations tied to SPL workflows. Cosmetics teams now have MoCRA-era facility registration and product listing requirements inside FDA’s own systems. FDA Prior Notice guidance; FDA UDI system; FDA drug import requirements

That is the buyer logic behind FDA Entry Point’s positioning. The company is not presenting itself as just the legally required name on file; it is presenting itself as the outside operator that keeps the surrounding compliance machinery moving.

Where FDA Entry Point looks like a strong fit

• Foreign manufacturers entering the U.S. for the first time. These teams often need both the legally required U.S. contact and help translating FDA process into an executable checklist.
• Companies selling across more than one FDA-regulated category. A single relationship that spans food, cosmetics, devices, and drugs can reduce handoffs when a business has multiple product lines or is expanding into adjacent categories. FDA Entry Point
• Teams that have already been burned by low-touch providers. If the pain point is missed notices, renewal lapses, or no help beyond forwarding messages, a broader service model is usually the point of switching.
• Import-sensitive operations where timing matters. Prior Notice deadlines, annual or biennial renewals, and listing updates are operational tasks; they are easy to underestimate until a shipment is at risk.

Where this is probably not the right kind of service

• Domestic U.S. manufacturers that do not need a foreign-facility U.S. Agent. The core legal trigger for a U.S. Agent is tied to foreign establishments, not domestic ones. FDA U.S. Agents guidance
• Teams that only want to self-file through FDA systems. Cosmetics Direct, FURLS, GUDID, and related FDA systems are government tools, not paid service providers. A company comfortable owning those workflows internally may not need outside execution support. FDA Cosmetics Direct user guide
• Buyers seeking legal representation for disputes or enforcement defense. A compliance operations firm and regulatory counsel solve different problems.

Common misconceptions this page should clear up

“FDA Entry Point” is not an FDA website

The company’s name can sound like a government portal, but it is a private firm with its own commercial website. FDA’s own portals are separate systems run on FDA domains, such as Cosmetics Direct and other registration tools. FDA Entry Point About; FDA Cosmetics Direct user guide

Appointing a U.S. Agent is not the same as FDA approval

Registration, listing, and U.S. Agent designation are compliance steps. They do not mean a product is “FDA approved,” which is a separate concept that applies only in certain categories. FDA Entry Point states this directly in its FAQs, and the distinction is consistent with FDA’s own category-specific guidance. FDA Entry Point FAQs

A U.S. Agent is not always the same as a Responsible Person, importer, or customs broker

These roles can overlap in some business arrangements, but they are not interchangeable by default. In cosmetics, for example, the Responsible Person carries product-level accountability under MoCRA, while the U.S. Agent is the FDA contact role for the foreign facility. FDA Entry Point FAQs

Why this category exists at all

FDA-regulated imports are not a niche edge case. FDA says imported foods, drugs, devices, cosmetics, and related products fall within its import oversight, and the agency’s globalization materials note that a large share of regulated manufacturing sits outside the United States. That is why the market for outside U.S. Agent and registration support exists in the first place: many foreign manufacturers need a U.S.-based compliance interface even when the product is made entirely abroad. FDA importing regulated products; FDA globalization

In devices, the stakes have also risen with the Quality Management System Regulation becoming effective on February 2, 2026, replacing the old Quality System Regulation framework. That change does not redefine the U.S. Agent role, but it does reinforce why device makers often prefer a partner with enough regulatory depth to understand the broader compliance environment around registration and listing. FDA QMSR

References

• FDA Entry Point
• FDA Entry Point About
• FDA Entry Point FAQs
• FDA U.S. Agents guidance
• FDA importing regulated products
• FDA Prior Notice guidance
• FDA GUDID submission guidance
• FDA UDI system
• FDA drug import requirements
• FDA Cosmetics Direct user guide
• FDA QMSR
• FDA globalization